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Abstract:  Cinnamic acid and its derivatives have shown a variety of pharmacologic 
properties. However, little is known about the antiglycation properties of cinnamic acid and 
its derivatives. The present study sought to characterize the protein glycation inhibitory 
activity of cinnamic acid and its derivatives in a bovine serum albumin (BSA)/fructose 
system. The results demonstrated that cinnamic acid and its derivatives significantly 
inhibited the formation of advanced glycation end products (AGEs) by approximately 
11.96–63.36% at a concentration of 1 mM. The strongest inhibitory activity against the 
formation of AGEs was shown by cinnamic acid. Furthermore, cinnamic acid and its 
derivatives reduced the level of fructosamine, the formation of N
ε-(carboxymethyl) lysine 
(CML), and the level of amyloid cross β-structure. Cinnamic acid and its derivatives also 
prevented oxidative protein damages, including effects on protein carbonyl formation and 
thiol oxidation of BSA. Our findings may lead to the possibility of using cinnamic acid and 
its derivatives for preventing AGE-mediated diabetic complications. 
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1. Introduction 
Chronic hyperglycemia causes non-enzymatic protein glycation by reducing sugars, such as glucose 
and fructose, which react with the free amino groups of protein to initiate a complex cascade of 
repeated condensations, rearrangements, oxidative modifications, ultimately forming advanced 
glycation end products (AGEs) [1,2]. It has been clearly demonstrated that the accumulation of AGEs 
in body tissue is the leading cause of several age-related degeneration, atherosclerosis and diabetic 
complications such as retinopathy, nephropathy and neuropathy [3–5]. A comprehensive review of the 
current scientific literature reveals that the inhibition of AGE formation is  one of the therapeutic 
approaches to prevent the progression of diabetic complications [6]. For example, aminoguanidine 
(AG), a small synthetic hydrazine-like compound, has shown promising results in terms of inhibition 
of AGE formation, and has received the most interest from a Phase III clinical trials perspective. 
However, the trial was terminated because it has shown some toxicity problems in diabetic 
nephropathy, such as flu-like symptoms, gastrointestinal problems and anemia [7,8]. In this regard, the 
effort has been directed in finding effective phytochemical compounds from dietary plants, fruits and 
herbal medicines against protein glycation [9–12].  
Cinnamic acid and its derivatives are often characteristic of a plant species or even of a particular 
organ or tissue of that plant (Figure 1). Previous studies have shown the pharmacological properties of 
cinnamic acid and its derivatives, including hepatoprotective [13], anti-oxidant [14], and anti-diabetic 
activities [15]. To the best of our knowledge, studies regarding the protein glycation inhibitory effect 
of cinnamic acid and its derivatives have not been investigated. Therefore, the purpose of the present 
study was carried out to determine the inhibitory effect of cinnamic acid and its derivatives (Figure 1) 
against bovine serum albumin (BSA) in fructose-mediated non-enzymatic glycation. Moreover, we 
also examined the inhibitory effect of cinnamic acid and its derivatives on oxidation-dependent 
damages to BSA induced by fructose. Finally, we investigated their ability to inhibit the formation of 
the major chemical AG structure, N
-(carboxymethyl)lysine (CML). 
Figure 1. Structure of cinnamic acid and its derivatives. 
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Figure 1. Cont. 
Compound R1 R 2 R 3 Chemical  name 
1  H  H  H  Cinnamic acid (CA) 
2 OH  H  H  o-Hydroxycinnamic acid (o-HCA) 
3 H  OH  H  m-Hydroxycinnamic acid(m-HCA) 
4 H  H  OH  p-Hydroxycinnamic acid (p-HCA) 
5 OCH3 H  H  o-Methoxycinnamic acid (o-MCA) 
6 H  OCH3 H  m-Methoxycinnamic acid (m-MCA) 
7 H  H  OCH3  p-Methoxycinnamic acid (p-MCA) 
2. Results and Discussion 
2.1. The Effect of Cinnamic Acid and Its Derivatives on AGEs Formation  
Figure 2 shows the effects of seven compounds at concentration of 1 mM on the total AGEs 
formation during 28 days of incubation. The fluorescent intensity of BSA incubated with fructose 
significantly increased about 7.8-fold when compared to BSA, indicating progressive formation of 
AGEs. When the glycation occurred in the presence of cinnamic acid, we observed that cinnamic acid 
significantly reduced the formation of AGEs by 63.36 ± 1.07%, as compared to BSA incubated with 
fructose. Upon the introduction of a hydroxyl group at the ortho-position of cinnamic acid (o-HCA), it 
was found that the percentage inhibition of AGE formation was 35.49 ± 1.73%. The addition of a 
hydroxyl residue in the cinnamic acid at the meta- or para- positions resulted in a significant loss of 
inhibitory activity (m-HCA = 11.96 ± 2.02%, and p-HCA = 16.95 ± 1.95%). Replacement of a 
hydroxyl residue in cinnamic acid by a methoxyl residue at the ortho- (o-MCA), meta- (m-MCA) or 
para-positions (p-MCA), produced respective percentage inhibitions of AGE formation of 20.25 ± 
2.17%, 21.45 ± 1.67% and 26.10 ± 1.58%. However, these compounds were less potent than AG 
(79.46 ± 0.38%), which was used as control. 
Protein glycation involves a series of complex reactions that occur between monosaccharides 
(glucose and fructose) and amino acids or proteins, which produce an unstable Schiff base, and then 
form an Amadori product such a fructosamine [1,2]. During the propagation reaction, the Amadori 
products react with the amino acids to form irreversible AGEs. According to the data obtained from 
this study, cinnamic acid was the strongest anti-glycating inhibitor among the compounds tested. Our 
findings also revealed that the presence of hydroxy or methoxy groups in cinnamic acid caused a 
significant decrease in the protein glycation inhibitory activity. The data presented here suggest that 
the presence of hydroxy or methoxy residues in cinnamic acid is not important for antiglycation 
activity. However, these findings are in contrast to our previous study reporting the structure-activity 
relationship of cinnamic acid and its derivatives on the inhibition of intestinal -glucosidase [16]. It is 
worth noting that cinnamic acid was found to be a weak inhibitor against intestinal maltase and sucrase 
[16]. In addition, the introduction of a hydroxyl group at various positions of the cinnamic acid 
molecule can increase intestinal maltase and sucrase inhibitory activities, whereas the presence of 
methoxy residue on cinnamic acid demonstrates less potent activity than the presence of hydroxy 
residue. In addition, it has been reported that cinnamic acid has no insulin secreting activity, whereas 
the introduction of hydroxy residues to cinnamic acid causes an increase in insulin secreting activity Int. J. Mol. Sci. 2012, 13                 
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from pancreatic β-cell [17]. Meanwhile, substitution of the hydroxy in cinnamic acid by the   
methoxy residue markedly increases the activity of insulin secretion. These findings suggest that 
adding hydroxy and methoxy residues in cinnamic acid is an important factor to exhibit   
insulinotropic activity. 
Figure 2. The effects of cinnamic acid and its derivatives (1 mM) and aminoguanidine 
(AG, 1 mM) on fluorescent AGEs formation in the BSA/fructose system. Each value 
represents the mean ± SEM (n=3). 
a P < 0.05 compared to BSA, 
b P < 0.05 compared to 
BSA +Fr (Fructose). 
 
2.2. The Effect of Cinnamic Acid and its Derivatives on the Level of Fructosamine and the Formation 
of CML 
After day 28 of the experiment, the level of fructosamine in BSA incubated with fructose produced 
a 4.5-fold increase compared to BSA (Figure 3). The results showed that cinnamic acid significantly 
decreased the level of fructosamine by about 44.3%. In addition, 6 other compounds suppressed the 
elevation of fructosamine by approximately 5.5%–40.0%, whereas AG caused a decrease in the level 
of fructosamine by 35.8%. Figure 4 shows the effect of cinnamic acid and its derivatives on   
protein-bound CML formation. The results showed that the formation of CML in BSA incubated with 
fructose was significantly 4.26-times higher than BSA incubated without fructose. The addition of 
cinnamic acid and its derivatives to the solution could reduce CML-derived AGE by approximately 
8.6–30.2%, whereas AG inhibited the formation of CML by 67.9% when compared to BSA incubated 
with fructose. Int. J. Mol. Sci. 2012, 13                 
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Figure 3. The effects of cinnamic acid and its derivatives (1 mM) and AG (1 mM) on the 
level of fructosamine in the BSA/fructose system. Each value represents the mean ± SEM 
(n = 3). 
a P < 0.05 compared to BSA, 
b P < 0.05 compared to BSA +Fr (Fructose). 
 
Figure 4. The effects of cinnamic acid and its derivatives (1 mM) and AG (1 mM) on the 
level of N
ε-(carboxymethyl) lysine (CML) in the BSA/fructose system. Each value 
represents the mean ± SEM (n = 3). 
a P < 0.05 compared to BSA, 
b P < 0.05 compared to 
BSA +Fr (Fructose). 
 
The determination of BSA fructosamine levels is used to monitor the accumulation of early 
(Amadori) glycation products. The results demonstrated that the reduced level of fructosamine by 
cinnamic acid and its derivatives was associated with the decreased formation of AGEs. Our results Int. J. Mol. Sci. 2012, 13                 
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suggest that cinnamic acid and its derivatives have an inhibitory effect on Amadori production, 
resulting in the prevention of conversion into AGEs. N
ε-(carboxymethyl) lysine (CML) is the most 
used marker for AGEs in humans [18]. This product can accumulate in tissues, causing increased 
inflammation, reduced antioxidant defense, and accelerated micro- and macrovasculopathies [19]. The 
findings indicate that cinnamic acid and its derivatives are effective in reducing CML formation 
associated with reduced levels of fructosamine.  
Cinnamon, used variously in food as a herb or spice, has been shown to ameliorate the symptoms of 
metabolic syndromes, such as insulin resistance, elevated levels of glucose and lipids and decreased 
antioxidant [20]. There are some reports in the literature showing that cinnamon extract exhibits potent 
inhibition of protein glycation [9,10]. The constituents of cinnamon bark are mainly cinnamic acid, 
cinnamaldehyde and cinnamic alcohol [21]. Therefore, it is possible that the reduced protein glycation 
of cinnamon extract observed in the previous study can be best explained by the inhibitory activity of 
cinnamic acid. 
2.3. The Effect of Cinnamic Acid and Its Derivatives on the Level of Amyloid Cross-β Structure 
As shown in Figure 5, the level of amyloid cross-β structure in BSA was determined by using 
thioflavin T, a fluorescent dye that specifically binds with fibrous structures. The fluorescent intensity 
of BSA incubated with fructose resulted in a 3.86-fold increased response, as compared with BSA 
incubated without fructose, suggesting that the protein glycation progressively induced the formation 
of amyloid cross-β structure in BSA. The results showed that cinnamic acid markedly decreased the 
fluorescent intensity of BSA incubated with fructose. Furthermore, reduced fluorescent intensity was 
also observed in BSA by incubation of fructose and the series of hydroxycinnamic acids (o-HCA,  
m-HCA, and p-HCA), whereas the presence of the series of methoxycinnamic acids (o-MCA, m-MCA, 
and p-MCA could decrease fluorescence intensity slightly. 
Figure 5. The effects of cinnamic acid and its derivatives (1mM) and AG (1 mM) on 
thioflavin T fluorescence in the BSA/fructose system. Each value represents the mean ± 
SEM (n = 3). 
a P < 0.05 compared to BSA, 
b P < 0.05 compared to BSA +Fr (Fructose). 
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Glycation is a key mechanism to induce the conformational changes of protein by increasing the 
level of amyloid cross β-structure, which plays a fundamental role in the protein aggregation. Studies 
reveal that the deposition of protein aggregation has been associated with the progression of several 
debilitating degenerative diseases including hemodialysis amyloidosis, diabetes, Parkinson’s disease 
and Alzheimer’s disease [22–24]. Notably, accumulation of protein aggregation causes pancreatic islet 
amyloidosis, which directly induces β-cell damage and impaired insulin secretion [25]. Our data 
clearly establish that cinnamic acid and its derivatives suppress in the level of amyloid cross   
β-structure of BSA. This beneficial effect of cinnamic acid and its derivatives may help to reduce a 
risk of developing debilitating degenerative diseases in diabetic patients.  
2.4. The Effect of Cinnamic Acid and its Derivatives on Glycation-Induced Protein Oxidation 
Table 1 shows the results for available free thiol groups and oxidative modification of BSA on 
cinnamic acid and its derivatives. A significant decrease in free thiol groups was observed in BSA 
incubated with fructose, indicating that protein glycation modified thiol groups to form disulfide in 
BSA. It found that cinnamic acid and its derivatives significantly reduced the oxidation of thiol groups 
by approximately 9.5–28.6%, whereas AG also protected the loss of protein thiol groups about 22.2%, 
as compared to BSA incubated with fructose.  
Table 1. The effects of cinnamic acid and its derivatives (1 mM) and AG (1 mM) on thiol 
group content and protein carbonyl formation of fructose-modified BSA. 
Compound 
Thiol group 
(nmol/mg protein) 
Protein carbonyl content 
(nmol/mg protein) 
BSA  0.89 ± 0.01  0.25 ± 0.02 
BSA+Fr  0.63 ± 0.03 
a  2.30 ± 0.08 
a 
BSA+Fr+ CA  0.75 ± 0.06 
b  1.90 ± 0.07 
b 
BSA+Fr+ o-HCA  0.71 ± 0.01 
b  1.88 ± 0.07 
b 
BSA+Fr+ m-HCA  0.69 ± 0.04 
b  1.97 ± 0.05 
b 
BSA+Fr+ p-HCA  0.80 ± 0.02 
b  1.84 ± 0.05 
b 
BSA+Fr+ o-MCA  0.76 ± 0.02 
b  1.75 ± 0.07 
b 
BSA+Fr+ m-MCA  0.76 ± 0.03 
b  1.84 ± 0.04 
b 
BSA+Fr+ p-MCA  0.74 ± 0.01 
b  1.71 ± 0.10 
b 
BSA+Fr+AG  0.81 ± 0.02 
b  1.59 ± 0.77 
b 
Each value represents the mean ± SE (n = 3). 
a P < 0.05 compared to BSA, 
b P < 0.05 compared to 
BSA + Fr (Fructose). 
The addition of fructose to the BSA solution for 28 days significantly increased the extent of 
protein carbonyl formation, compared to BSA in the absence of fructose. It found that cinnamic acid 
and its derivatives suppressed protein carbonyl formation by approximately 18.2–25.7% when 
compared to BSA incubated with fructose. In addition, AG reduced protein carbonyl formation in BSA 
incubated with fructose by 30.9%. 
In general, glycation and AGE-induced toxicity are known to be associated with increased free 
radical production [2]. In particular, the process of oxidative degradation of Amadori intermediates can 
generate free radicals, causing damage by oxidizing proteins [26]. Major molecular modifications of Int. J. Mol. Sci. 2012, 13                 
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protein structural changes can be investigated by protein carbonyl formations and the loss of protein 
thiol groups [27]. Moreover, the investigation of thiol group in BSA is the direct reflection of excess 
free radical generation [27]. The marked increase in protein carbonyl formation and the oxidation of 
thiols in BSA were observed fructose incubation. Our findings show that the addition of cinnamic acid 
and its derivatives together with fructose to a BSA solution significantly suppresses the protein 
carbonyl formation and oxidation of thiols. There is considerable evidence to support the argument that 
trapping free radicals and reactive carbonyl group formation by antioxidant compounds is a strategy 
for the inhibition of protein glycation [6]. Recently, cinnamic acid and its derivatives have shown 
favorable effects in antioxidant properties [10]. It can be assumed that the mechanism of cinnamic acid 
and its derivatives for lowering protein glycation may be related to their antioxidant activity. However, 
the antioxidant activity of cinnamic acid and its derivatives may not be the only reason to explain the 
antiglycating mechanism. Biochemical mechanisms of anti-glycation reactions have been recently 
proposed, such as breaking the cross-linking structures in AGEs that have been formed, blocking the 
carbonyl or dicarbonyl groups in reducing sugars, Schiff bases or Amadori and inhibiting the 
formation of late-stage Amadori products [6]. Further comprehensive studies of cinnamic acid and its 
derivatives are required to evaluate the antiglycating mechanisms described above. 
3. Experimental Section  
3.1. Chemicals 
o-Hydroxycinnamic acid (o-HCA), m-hydroxycinnamic acid (m-HCA) and p-hydroxycinnamic acid 
(p-HCA) were purchased from Fluka (St. Louis, MO). o-Methoxycinnamic acid (o-MCA),  
m-methoxycinnamic acid (m-MCA) and p-methoxycinnamic acid (p-MCA) were purchased from 
ACROS (Pittsburgh, PA, USA). Cinnamic acid, bovine serum albumin (BSA, fraction V), 
aminoguanidine hydrochloride, guanidine hydrochloride, thioflavin T, 5,5'-Dithiobis(2-nitrobenzoic 
acid), nitroblue-tetrazolium and L-cysteine were purchased from Sigma-Aldrich Co. (St. Louis, MO, 
USA). Fructose and 2,4-dinitrophenyl hydrazine were purchased from Ajax Finechem (Taren Point, 
Australia). Trichloroacetic acid was purchased from Merck (Darmstadt, FR, Germany). OxiSelect™ 
N
ε-(carboxymethyl) lysine (CML) ELISA kit was obtained from Cell Biolabs (San Diego, CA, USA). 
All other chemicals and solvents used in this study were of analytical grade. 
3.2. Glycation of Bovine Serum Albumin (BSA) 
The glycated BSA formation was undertaken in accordance with a previous method with a minor  
modification [28]. In brief, BSA (10 mg/ml) was incubated with 500 mM fructose in a 0.1 M 
phosphate buffered-saline, pH = 7.4 containing 0.02% sodium azide in the dark at 37 °C for 28 days. 
Before incubation, cinnamic acid and its derivatives and aminoguanidine (final concentration: 1 mM) 
were added to the mixtures. Dimethylsulfoxide (DMSO) was used for a solvent for this study (final 
concentration: 4.0%). The glycated BSA formation was measured by using fluorescent intensity at an 
excitation wavelength 355 nm and emission wavelength 460 nm.  
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3.3. Determination of Fructosamine 
The concentration of fructosamine, the Amadori product, was measured by using the   
nitroblue-tetrazolium (NBT) assay [29]. Briefly, glycated BSA was incubated with 0.5 mM NBT in  
0.1 M carbonate buffer, pH = 10.4 at 37 °C. The absorbance was measured at 530 nm. The 
concentration of fructosamine was calculated using the different absorption at the time point of   
10 and 15 min, and compared to 1-deoxy-1-morpholino-fructose (1-DMF) as the standard. 
3.4. Determination of N
ε-(Carboxymethyl) Lysine (CML) 
N
ε-(carboxymethyl) lysine (CML), a major AGE structure, was determined by using enzyme linked 
immunosorbant assay (ELISA) kit. The concentration of CML was calculated by using the standard 
CML-BSA curve from the assay kit.  
3.5. Determination of Amyloid Cross β Structure 
Thioflavin T, a marker of amyloid cross β structure, was measured according a previous method 
with minor modifications [30]. Briefly, glycated BSA was incubated with 32 µM thioflavin T in 0.1 M 
PBS, pH = 7.4. After 60 min incubation, the fluorescence intensity was measured at an excitation 
wavelength of 435 nm and an emission wavelength of 485 nm.  
3.6. Determination of Protein Carbonyl Content 
Carbonyl group in glycated BSA, a marker for protein oxidative damage, was assayed according to 
a previous method [31]. In brief, glycated BSA was incubated with 10 mM 2,4-dinitrophenylhydrazine 
(DNPH) in 2.5 M HCl at room temperature for 60 min. Afterwards, glycated BSA was precipitated by 
20% (w/v) trichloroacetic acid (TCA), left on ice for 5 min, and centrifuged at 10,000g for 10 min at  
4° C. The pellet was washed three times using 500 µL of 1:1 (v/v) ethanol:ethyl acetate mixture. The 
final pellet was dissolved in 6 M guanidine hydrochloride. The absorbance was read at 370 nm. The 
protein carbonyl group concentration was calculated by using absorption coefficient   
( = 22,000 M
−1·cm
−1). The results were expressed as nmol carbonyls/mg protein.  
3.7. Thiol Group Estimation 
The free thiol groups of glycated BSA were measured according to Ellman’s assay with slight 
modifications [32]. Briefly, glycated BSA was incubated with 5 mM 5,5'-dithiobis(2-nitrobenzoic 
acid) (DTNB) in 0.1 M PBS, pH 7.4 for 15 min. Thereafter, the absorbance was measured at 412 nm. 
The free thiol concentration was calculated by using L-cysteine as standard curve. The results were 
expressed as nmol/mg protein.  Int. J. Mol. Sci. 2012, 13                 
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3.8. Statistical Analysis 
The results were expressed as the mean ± standard error of the mean (SEM) (n = 3). The statistical 
significance of the results was evaluated by using one-way ANOVA. The least significant difference 
(LSD) test was used for mean comparisons, and P < 0.05 was considered to be statistically significant. 
4. Conclusions  
We found that cinnamic acid and its derivatives could effectively protect BSA from fructose-mediated 
protein glycation in vitro. They also reduced the level of fructosamine, the formation of CML and the 
amyloid cross β-structure in BSA. In addition, cinnamic acid and its derivatives significantly decreased 
the protein carbonyl content and increased the level of protein thiol. These findings may be applied for 
prevention or management of AGE-mediated pathologies, particularly for those who are at risk of 
developing diabetic complications. 
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